Analysis of diagnosis and treatment of Epstein-Barr virus-negative diffuse large B-cell lymphoma (GCB type) after kidney transplantation
10.12464/j.issn.1674-7445.2025290
- VernacularTitle:肾移植术后EB病毒阴性弥漫性大B细胞淋巴瘤（GCB型）的诊疗分析
- Author:
Yan LI
1
;
Xiaoyan ZHANG
1
;
Xiang REN
1
;
Tong XU
1
;
Guohui WANG
1
;
Ruochen QI
1
;
Dongjuan WU
1
;
Kepu LIU
1
;
Weijun QIN
1
;
Shuaijun MA
1
Author Information
1. Department of Urology, the First Affiliated Hospital of Air Force Medical University of People's Liberation Army of China, Xi'an 710032, China.
- Publication Type:OriginalArticle
- Keywords:
Kidney transplantation;
Epstein-Barr virus;
Posttransplant lymphoproliferative disease;
EB virus-negative diffuse large B-cell lymphoma;
Rituximab;
Immunosuppression;
Lymphocyte;
Hemodialysis
- From:
Organ Transplantation
2026;17(2):257-265
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical and therapeutic characteristics of Epstein-Barr virus (EBV)-negative posttransplant lymphoproliferative disease (PTLD) with diffuse large B-cell lymphoma (DLBCL) in the context of specific cases and literature. Methods A case of EBV-negative DLBCL (GCB type) after kidney transplantation is reported. The patient was a 45-year-old male who underwent living-related kidney transplantation in 2016 and has been receiving triple immunosuppressive therapy with tacrolimus, mycophenolate mofetil and methylprednisolone since then. In 2024, the patient presented with intermittent fever, night sweats and gastrointestinal symptoms. The diagnosis was confirmed by endoscopic pathology, immunohistochemical staining and positron emission tomography/computed tomography. The R-CDOP regimen (rituximab + cyclophosphamide + liposomal doxorubicin + vincristine + dexamethasone) was used for treatment. Results The patient was diagnosed with EBV-negative DLBCL (GCB type, Ann Arbor stage Ⅳ B). After 4 cycles of R-CDOP chemotherapy, the efficacy assessment was partial remission, and the transplant kidney function remained stable. Conclusions For EBV-negative PTLD after kidney transplantation, it is necessary to break through the "virus-dependent" diagnostic thinking. In clinical practice, the focus should be on protecting the transplant kidney, and individualized treatment plans should be developed for patients.
